Sage Therapeutics Inc (NASDAQ:SAGE) price on Wednesday, January 15, fall -2.42% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $7.26.
A look at the stock’s price movement, the close in the last trading session was $7.44, moving within a range at $7.2 and $7.6. The beta value (5-Year monthly) was 0.924. Turning to its 52-week performance, $27.67 and $4.62 were the 52-week high and 52-week low respectively. Overall, SAGE moved 28.04% over the past month.
Sage Therapeutics Inc’s market cap currently stands at around $444.12 million, with investors looking forward to this quarter’s earnings report slated for in February.
Analysts have a consensus estimate of 14.11M for the company’s revenue for the quarter, with a low and high estimate of 10.35M and 17.4M respectively. The average forecast suggests down to a -81.90% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 42.22M, representing a -51.16% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that SAGE is a Hold. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 4 analyst(s) rate the stock as a Hold, 3 recommend SAGE as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
SAGE’s current price about 24.08% and 27.55% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 66.24, while 7-day volatility ratio is 5.31% and 7.64% in the 30-day chart. Further, Sage Therapeutics Inc (SAGE) has a beta value of 0.86, and an average true range (ATR) of 0.52. Analysts have given the company’s stock an average 52-week price target of $13, forecast between a low of $5 and high of $26. Looking at the price targets, the low is 31.13% off current price level while to achieve the yearly target high, price needs to move -258.13%. Nonetheless, investors will most likely welcome a -79.06% jump to $13 which is the analysts’ median price.
If we refocus on Sage Therapeutics Inc (NASDAQ:SAGE), historical trading data shows that trading volumes averaged 2.58 over the past 10 days and 1.30 million over the past 3 months. The company’s latest data on shares outstanding shows there are 61.17 million shares.
The 11.92% of Sage Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 85.19% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.83 million on 2024-12-31, giving us a short ratio of 3.46. The data shows that as of 2024-12-31 short interest in Sage Therapeutics Inc (SAGE) stood at 894.99995 of shares outstanding, with shares short falling to 6.53 million registered in 2024-11-29. Current price change has pushed the stock 33.70% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SAGE stock continues to rise going into the next quarter.
